트랜스펙션 기술 시장 규모, 점유율, 동향 및 예측 : 제품 유형, 용도, 트랜스펙션 방법, 기술, 최종사용자, 지역별(2026-2034년)

The global transfection technologies market size was valued at USD 1,348.6 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 2,431.3 Million by 2034, exhibiting a CAGR of 6.56% from 2026-2034. North America currently dominates the market, holding a market share of 39.3% in 2025. The transfection technologies market share is growing because of strong research infrastructure, high healthcare spending, widespread adoption of advanced genomic tools, significant biotech and pharma presence, and supportive government funding for genetic research and drug discovery.

Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.

The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.

Market Segmentation

This report provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2026-2034. The report has categorized the market based on product type, application, transfection method, technology and end-user.

Breakup by Product Type

• Reagent
• Instrument
• Others

Breakup by Application

• Therapeutic Delivery
• Bio-Medical Research
• Protein Production
• Others

Breakup by Transfection Method

• Lipofection
• Eletroporation
• Nucleofection
• Cotransfection
• Cationic Lipid Transfection
• In-Vivo Transfection
• Others

Breakup by Technology

• Physical Transfection
• Biochemical Based Transfection
• Viral-Vector Based Transfection

Breakup by End-User

• Research Centers and Academic Institutes
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Breakup by Region

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.

Key Questions Answered in This Report

1. What was the size of the global transfection technologies market in 2025?

2. What is the expected growth rate of the global transfection technologies market during 2026-2034?

3. What are the key factors driving the global transfection technologies market?

4. What has been the impact of COVID-19 on the global transfection technologies market?

5. What is the breakup of the global transfection technologies market based on the product type?

6. What is the breakup of the global transfection technologies market based on the application?

7. What is the breakup of the global transfection technologies market based on the transfection method?

8. What is the breakup of the global transfection technologies market based on the technology?

9. What are the key regions in the global transfection technologies market?

10. Who are the key players/companies in the global transfection technologies market?10. Who are the key players/companies in the global transfection technologies market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transfection Technologies Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Reagent
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instrument
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Therapeutic Delivery
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Bio-Medical Research
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Protein Production
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Transfection Method

• 8.1 Lipofection
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Eletroporation
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Nucleofection
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Cotransfection
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Cationic Lipid Transfection
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 In-Vivo Transfection
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Technology

• 9.1 Physical Transfection
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Biochemical Based Transfection
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Viral-Vector Based Transfection
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End-User

• 10.1 Research Centers and Academic Institutes
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospitals and Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Pharmaceutical and Biotechnology Companies
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Altogen Biosystems
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Amsbio
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Bio-RAD Laboratories Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Lonza Group AG
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Maxcyte Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Mirus Bio LLC
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Promega Corporation
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 QIAGEN N.V.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Sartorius AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 SignaGen Laboratories
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Takara Bio Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Thermo Fisher Scientific Inc.
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis